Inhaled corticosteroids are used by millions of asthma patients every day. However, as with all treatments to control asthma, there is marked patient-to-patient variability in the response to treatment. New research published today in the New England Journal of Medicine (NEJM) has identified a genetic variant associated with the response to inhaled corticosteroids . Investigators have found that asthma patients who have two copies of a specific gene variant responded only one-third as well to steroid inhalers as those with two copies of the regular gene.
Earlier this month, Indiana University announced a major commitment to research in one of healthcare’s most promising fields, personalized medicine. The Indiana Institute for Personalized Medicine will pursue genome-based and pharmacogenomics studies in cardiology, pediatrics, obstetrics and cancer, as well as other areas . The emergence of personalized medicine, which targets individualized treatment and care based on personal and genetic variation, is creating a thriving market. Indeed, the market for personalized medicine in the United States is $232 billion and is projected to grow 11% annually .
Small genetic differences between individuals help explain why some people have a higher risk than others for developing illnesses such as diabetes or cancer. Recently in the journal Nature, the 1000 Genomes Project, an international public-private consortium, published the most comprehensive map of these genetic differences, called variations, estimated to contain approximately 95 percent of the genetic variation of any person on Earth.